Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026

Group 1 - Bristol-Myers Squibb Company (BMY) is ranked second among the Top 10 Oncology Stocks to Buy Now, indicating strong investor interest in the company [1] - Scotiabank analyst Louise Chen raised BMY's price target to $60 from $53, citing the stock's low valuation and a "catalyst-rich" outlook for 2026 [1][2] - The company announced positive topline results from its Phase 3 SCOUT-HCM trial for Camzyos (mavacamten) in teenagers with symptomatic obstructive hypertrophic cardiomyopathy, fulfilling primary and secondary endpoints [2][3] Group 2 - Bristol-Myers Squibb is recognized as a global biopharmaceutical leader in oncology, focusing on innovative immuno-oncology and targeted therapies across various cancer types [3] - The company has a robust clinical pipeline and a strong legacy in cancer research and development, positioning it well for future growth [3]